NO995819L - Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase - Google Patents

Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase

Info

Publication number: NO995819L
Authority: NO; Norway
Prior art keywords: p561ck; quinoline; growth factor; tyrosine kinase; derived growth
Prior art date: 1997-05-28

Application number

NO995819A

Other languages

English (en)

Other versions

NO323721B1 (no

NO995819D0 (no

Inventor

Michael R Myers

Alfred P Spada

Paul E Persons

Martin P Maguire

Original Assignee

Rhone Poulenc Rorer Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-28

Filing date

1999-11-26

Publication date

1999-11-26

1999-11-26 Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma

1999-11-26 Publication of NO995819L publication Critical patent/NO995819L/no

1999-11-26 Publication of NO995819D0 publication Critical patent/NO995819D0/no

2007-06-25 Publication of NO323721B1 publication Critical patent/NO323721B1/no

Links

SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 title 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 title 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/54—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)

NO19995819A 1997-05-28 1999-11-26 Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56lck-tyrosinkinase og farmasoytisk formulering inneholdende det samme, samt anvendelse derav NO323721B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86445597A	1997-05-28	1997-05-28
US97261497A	1997-11-18	1997-11-18
PCT/US1998/010999 WO1998054156A1 (en)	1997-05-28	1998-05-28	QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES

Publications (3)

Publication Number	Publication Date
NO995819L true NO995819L (no)	1999-11-26
NO995819D0 NO995819D0 (no)	1999-11-26
NO323721B1 NO323721B1 (no)	2007-06-25

Family

ID=27127839

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19995818A NO323720B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
NO19995819A NO323721B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56lck-tyrosinkinase og farmasoytisk formulering inneholdende det samme, samt anvendelse derav
NO19995817A NO316377B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56<O>lck</O>-tyrosinkinase, farmas degree ytisk blandinginneholdende detsamme samt anvendelse derav

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO19995818A NO323720B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO19995817A NO316377B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56<O>lck</O>-tyrosinkinase, farmas degree ytisk blandinginneholdende detsamme samt anvendelse derav

Country Status (25)

Country	Link
EP (3)	EP0991628B1 (no)
JP (3)	JP2002500675A (no)
KR (2)	KR100440756B1 (no)
CN (3)	CN1261353A (no)
AP (3)	AP1554A (no)
AT (3)	ATE286886T1 (no)
AU (3)	AU742739B2 (no)
BG (3)	BG64444B1 (no)
BR (3)	BR9809515A (no)
CA (3)	CA2291728A1 (no)
CZ (3)	CZ298521B6 (no)
DE (3)	DE69828607T2 (no)
DK (1)	DK0991628T3 (no)
EA (4)	EA008136B1 (no)
ES (1)	ES2235331T3 (no)
HU (2)	HUP0002084A3 (no)
IL (3)	IL133007A (no)
NO (3)	NO323720B1 (no)
OA (3)	OA11264A (no)
PL (3)	PL194670B1 (no)
PT (1)	PT991628E (no)
SI (1)	SI0991628T1 (no)
SK (4)	SK286084B6 (no)
UA (1)	UA57790C2 (no)
WO (3)	WO1998054156A1 (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU742739B2 (en) *	1997-05-28	2002-01-10	Aventis Pharmaceuticals Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56 lck tyrosine kinases
US6180632B1 (en) *	1997-05-28	2001-01-30	Aventis Pharmaceuticals Products Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6159978A (en)	1997-05-28	2000-12-12	Aventis Pharmaceuticals Product, Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) *	1997-05-28	2001-06-12	Aventis Pharmaceuticals Products, Inc	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9904103D0 (en)	1999-02-24	1999-04-14	Zeneca Ltd	Quinoline derivatives
US6506769B2 (en)	1999-10-06	2003-01-14	Boehringer Ingelheim Pharmaceuticals, Inc.	Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en)	1999-11-30	2006-09-05	Pfizer Inc.	2,4-diaminopyrimidine compounds useful as immunosuppressants
MXPA03001306A (es)	2000-08-11	2003-10-15	Boehringer Ingelheim Pharma	Compuestos heterociclicos utiles como inhibidores de las quinasas de tirosina.
SI1497266T1 (sl)	2002-03-27	2008-10-31	Glaxo Group Ltd	Derivati kinolina in njihova uporaba kot ligandi 5-ht6
DE10237423A1 (de) *	2002-08-16	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1558582B1 (en)	2003-07-22	2005-12-21	Arena Pharmaceuticals, Inc.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
CA2553729A1 (en)	2004-01-16	2005-08-04	Wyeth	Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
PE20090288A1 (es)	2007-05-10	2009-04-03	Smithkline Beecham Corp	Derivados de quinoxalina como inhibidores de la pi3 quinasa
EP2254564A1 (en)	2007-12-12	2010-12-01	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP2241557A1 (de)	2009-04-02	2010-10-20	Æterna Zentaris GmbH	Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
JP5728683B2 (ja)	2009-09-04	2015-06-03	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
CN101823998B (zh) *	2010-05-05	2015-03-25	江苏利田科技股份有限公司	一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
WO2012048181A1 (en)	2010-10-08	2012-04-12	N30 Pharmaceuticals, Llc	Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
BR112013014681A2 (pt)	2010-12-16	2016-10-04	N30 Pharmaceuticals Inc	novos compostos aromáticos bicíclicos substituídos como inibidores de s-nitrosoglutationa redutase
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118652D0 (en) *	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
JP6166289B2 (ja)	2012-03-14	2017-07-19	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換イミダゾピリダジン
SI3459942T1 (sl)	2012-04-24	2021-05-31	Vertex Pharmaceuticals Incorporated	Inhibitorji DNA-PK
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209609D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
LT3495367T (lt)	2012-06-13	2021-02-25	Incyte Holdings Corporation	Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
HUE041544T2 (hu)	2013-03-12	2019-05-28	Vertex Pharma	DNS-PK inhibitorok
LT2986610T (lt)	2013-04-19	2018-04-10	Incyte Holdings Corporation	Bicikliniai heterociklai, kaip fgfr inhibitoriai
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
PE20160156A1 (es)	2013-06-11	2016-04-20	Bayer Pharma AG	Derivados de prodroga de triazolpiridinas sustituidas
PT3424920T (pt)	2013-10-17	2020-07-07	Vertex Pharma	Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk
MA39784B1 (fr)	2014-03-26	2021-03-31	Astex Therapeutics Ltd	Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
AU2015238305B2 (en)	2014-03-26	2020-06-18	Astex Therapeutics Ltd	Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
JO3695B1 (ar)	2015-02-10	2020-08-27	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
SG11201706287PA (en)	2015-02-20	2017-09-28	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
HK1245660A1 (zh)	2015-06-12	2018-08-31	Axovant Sciences Gmbh	有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en)	2015-07-15	2017-01-19	Axovant Sciences Ltd.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US10399946B2 (en)	2015-09-10	2019-09-03	Laurel Therapeutics Ltd.	Solid forms of an S-Nitrosoglutathione reductase inhibitor
CN108137546B (zh)	2015-09-23	2021-07-27	詹森药业有限公司	双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
KR102703498B1 (ko)	2015-09-23	2024-09-04	얀센 파마슈티카 엔브이	신규 화합물
JP2019529475A (ja)	2016-09-27	2019-10-17	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020011718A (es)	2018-05-04	2021-02-15	Incyte Corp	Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en)	2018-05-04	2026-04-07	Incyte Corp	Salts of an fgfr inhibitor
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Derivatives of an fgfr inhibitor
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352060A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja)	2021-06-09	2024-06-11	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1288436C (en) *	1983-07-22	1991-09-03	David Paul Hesson	Phenylquinolinecarboxylic acids and derivatives as antitumor agents
US4888427A (en) *	1987-04-07	1989-12-19	University Of Florida	Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
GB9004483D0 (en) *	1990-02-28	1990-04-25	Erba Carlo Spa	New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2102780C (en) *	1991-05-10	2007-01-09	Alfred P. Spada	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
NO306992B1 (no) *	1993-01-28	2000-01-24	Takeda Chemical Industries Ltd	Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene
DE4426373A1 (de) *	1994-07-26	1996-02-01	Bayer Ag	3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung
CA2260999C (en) *	1996-07-19	2006-07-11	Takeda Chemical Industries, Ltd.	Heterocyclic compounds, their production and use in tyrosine kinase inhibition
AU5574798A (en) *	1997-01-21	1998-08-07	Nissan Chemical Industries Ltd.	Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines
AU742739B2 (en) *	1997-05-28	2002-01-10	Aventis Pharmaceuticals Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56 lck tyrosine kinases

1998
- 1998-05-28 AU AU78037/98A patent/AU742739B2/en not_active Ceased
- 1998-05-28 PL PL98337084A patent/PL194670B1/pl not_active IP Right Cessation
- 1998-05-28 CA CA002291728A patent/CA2291728A1/en not_active Abandoned
- 1998-05-28 HU HU0002084A patent/HUP0002084A3/hu unknown
- 1998-05-28 WO PCT/US1998/010999 patent/WO1998054156A1/en not_active Ceased
- 1998-05-28 JP JP50096599A patent/JP2002500675A/ja not_active Ceased
- 1998-05-28 CZ CZ0415899A patent/CZ298521B6/cs not_active IP Right Cessation
- 1998-05-28 DE DE69828607T patent/DE69828607T2/de not_active Expired - Lifetime
- 1998-05-28 CN CN98806430A patent/CN1261353A/zh active Pending
- 1998-05-28 AT AT98925022T patent/ATE286886T1/de not_active IP Right Cessation
- 1998-05-28 SK SK114-2005A patent/SK286084B6/sk not_active IP Right Cessation
- 1998-05-28 BR BR9809515-3A patent/BR9809515A/pt not_active Application Discontinuation
- 1998-05-28 AT AT98925041T patent/ATE500233T1/de not_active IP Right Cessation
- 1998-05-28 AU AU77079/98A patent/AU751188C/en not_active Ceased
- 1998-05-28 PL PL337086A patent/PL194980B1/pl unknown
- 1998-05-28 AP APAP/P/1999/001710A patent/AP1554A/en active
- 1998-05-28 AP APAP/P/1999/001711A patent/AP1362A/en active
- 1998-05-28 CN CN98806454A patent/CN1280572A/zh active Pending
- 1998-05-28 CN CNB98806538XA patent/CN1140516C/zh not_active Expired - Fee Related
- 1998-05-28 JP JP50096499A patent/JP2002513417A/ja not_active Ceased
- 1998-05-28 CA CA002291774A patent/CA2291774A1/en not_active Abandoned
- 1998-05-28 KR KR10-1999-7011036A patent/KR100440756B1/ko not_active Expired - Fee Related
- 1998-05-28 ES ES98925022T patent/ES2235331T3/es not_active Expired - Lifetime
- 1998-05-28 UA UA99127137A patent/UA57790C2/uk unknown
- 1998-05-28 CA CA002291750A patent/CA2291750A1/en not_active Abandoned
- 1998-05-28 IL IL13300798A patent/IL133007A/xx not_active IP Right Cessation
- 1998-05-28 DK DK98925022T patent/DK0991628T3/da active
- 1998-05-28 IL IL13300998A patent/IL133009A0/xx not_active IP Right Cessation
- 1998-05-28 EA EA199901092A patent/EA008136B1/ru not_active IP Right Cessation
- 1998-05-28 EA EA199901086A patent/EA002600B1/ru not_active IP Right Cessation
- 1998-05-28 WO PCT/US1998/011036 patent/WO1998054158A1/en not_active Ceased
- 1998-05-28 SK SK1579-99A patent/SK157999A3/sk unknown
- 1998-05-28 DE DE69842151T patent/DE69842151D1/de not_active Expired - Lifetime
- 1998-05-28 KR KR10-1999-7010972A patent/KR100425638B1/ko not_active Expired - Fee Related
- 1998-05-28 CZ CZ0418099A patent/CZ296845B6/cs not_active IP Right Cessation
- 1998-05-28 AP APAP/P/1999/001709A patent/AP1444A/en active
- 1998-05-28 DE DE69842077T patent/DE69842077D1/de not_active Expired - Lifetime
- 1998-05-28 AU AU77062/98A patent/AU747026B2/en not_active Ceased
- 1998-05-28 BR BR9809501-3A patent/BR9809501A/pt not_active Application Discontinuation
- 1998-05-28 BR BR9809172-7A patent/BR9809172A/pt not_active Application Discontinuation
- 1998-05-28 CZ CZ0417999A patent/CZ298490B6/cs not_active IP Right Cessation
- 1998-05-28 SK SK1581-99A patent/SK158199A3/sk unknown
- 1998-05-28 EA EA199901090A patent/EA004103B1/ru not_active IP Right Cessation
- 1998-05-28 EP EP98925022A patent/EP0991628B1/en not_active Expired - Lifetime
- 1998-05-28 WO PCT/US1998/011000 patent/WO1998054157A1/en not_active Ceased
- 1998-05-28 PT PT98925022T patent/PT991628E/pt unknown
- 1998-05-28 AT AT98926129T patent/ATE493389T1/de not_active IP Right Cessation
- 1998-05-28 PL PL98337087A patent/PL195552B1/pl not_active IP Right Cessation
- 1998-05-28 IL IL13300898A patent/IL133008A0/xx not_active IP Right Cessation
- 1998-05-28 SI SI9830741T patent/SI0991628T1/ unknown
- 1998-05-28 EP EP98925041A patent/EP1001945B1/en not_active Expired - Lifetime
- 1998-05-28 HU HU0004807A patent/HUP0004807A3/hu unknown
- 1998-05-28 JP JP50098799A patent/JP2002500676A/ja not_active Ceased
- 1998-05-28 SK SK1580-99A patent/SK158099A3/sk unknown
- 1998-05-28 EP EP98926129A patent/EP1001946B1/en not_active Expired - Lifetime
1999
- 1999-11-23 EA EA200100575A patent/EA007807B1/ru not_active IP Right Cessation
- 1999-11-26 NO NO19995818A patent/NO323720B1/no unknown
- 1999-11-26 NO NO19995819A patent/NO323721B1/no unknown
- 1999-11-26 NO NO19995817A patent/NO316377B1/no unknown
- 1999-11-29 OA OA9900260A patent/OA11264A/en unknown
- 1999-11-29 OA OA9900262A patent/OA11222A/en unknown
- 1999-11-29 OA OA9900261A patent/OA11221A/en unknown
- 1999-12-08 BG BG103963A patent/BG64444B1/bg unknown
- 1999-12-08 BG BG103965A patent/BG64419B1/bg unknown
- 1999-12-14 BG BG104006A patent/BG64445B1/bg unknown

Also Published As

Publication number	Publication date
NO995818D0 (no)	1999-11-26
CN1261354A (zh)	2000-07-26
ATE286886T1 (de)	2005-01-15
WO1998054156A1 (en)	1998-12-03
AP1444A (en)	2005-07-18
EA200100575A1 (ru)	2002-02-28
NO995817L (no)	1999-11-26
EP1001946A1 (en)	2000-05-24
BG103965A (en)	2000-07-31
CZ298521B6 (cs)	2007-10-24
CA2291774A1 (en)	1998-12-03
AU7707998A (en)	1998-12-30
CZ415899A3 (cs)	2000-05-17
HUP0002084A3 (en)	2000-12-28
JP2002500676A (ja)	2002-01-08
BG104006A (en)	2000-07-31
AP9901710A0 (en)	1999-12-31
EA004103B1 (ru)	2003-12-25
HUP0002084A2 (hu)	2000-10-28
OA11221A (en)	2003-07-16
DE69828607D1 (de)	2005-02-17
CZ418099A3 (cs)	2000-05-17
AP9901709A0 (en)	1999-12-31
EP1001946A4 (en)	2000-07-26
UA57790C2 (uk)	2003-07-15
ES2235331T3 (es)	2005-07-01
CN1140516C (zh)	2004-03-03
NO995818L (no)	1999-11-26
KR100425638B1 (ko)	2004-04-03
CZ298490B6 (cs)	2007-10-17
AU742739B2 (en)	2002-01-10
PT991628E (pt)	2005-05-31
BR9809501A (pt)	2000-06-20
AU7706298A (en)	1998-12-30
EP1001945A4 (en)	2000-07-26
PL195552B1 (pl)	2007-10-31
PL337084A1 (en)	2000-07-31
BG64445B1 (en)	2005-02-28
JP2002500675A (ja)	2002-01-08
JP2002513417A (ja)	2002-05-08
KR20010013057A (ko)	2001-02-26
EA007807B1 (ru)	2007-02-27
AU751188B2 (en)	2002-08-08
EA199901086A1 (ru)	2000-06-26
IL133007A0 (en)	2001-03-19
EA199901092A1 (ru)	2000-06-26
CA2291728A1 (en)	1998-12-03
ATE500233T1 (de)	2011-03-15
BR9809515A (pt)	2000-06-20
OA11264A (en)	2002-11-19
AU751188C (en)	2005-06-30
NO316377B1 (no)	2004-01-19
NO323720B1 (no)	2007-06-25
NO323721B1 (no)	2007-06-25
EP0991628B1 (en)	2005-01-12
WO1998054158A1 (en)	1998-12-03
SK157999A3 (en)	2000-06-12
CA2291750A1 (en)	1998-12-03
PL194670B1 (pl)	2007-06-29
BG64419B1 (bg)	2005-01-31
EP0991628A4 (en)	2000-07-26
PL337087A1 (en)	2000-07-31
AP1362A (en)	2005-01-19
AU7803798A (en)	1998-12-30
IL133007A (en)	2005-06-19
EP1001945A1 (en)	2000-05-24
BG64444B1 (en)	2005-02-28
OA11222A (en)	2003-07-16
SK158199A3 (en)	2000-06-12
KR20010039512A (ko)	2001-05-15
HUP0004807A2 (hu)	2001-11-28
EA008136B1 (ru)	2007-04-27
CN1280572A (zh)	2001-01-17
EP0991628A1 (en)	2000-04-12
DE69842151D1 (de)	2011-04-14
CZ296845B6 (cs)	2006-07-12
NO995817D0 (no)	1999-11-26
CN1261353A (zh)	2000-07-26
BG103963A (en)	2000-07-31
KR100440756B1 (ko)	2004-07-21
IL133009A0 (en)	2001-03-19
WO1998054157A1 (en)	1998-12-03
PL337086A1 (en)	2000-07-31
HUP0004807A3 (en)	2001-12-28
SK286084B6 (sk)	2008-03-05
SI0991628T1 (en)	2005-06-30
EP1001945B1 (en)	2011-03-02
CZ417999A3 (cs)	2000-05-17
EP1001946B1 (en)	2010-12-29
DK0991628T3 (da)	2005-05-17
AP9901711A0 (en)	1999-12-31
ATE493389T1 (de)	2011-01-15
SK158099A3 (en)	2000-06-12
EA199901090A1 (ru)	2000-08-28
AP1554A (en)	2006-01-18
AU747026B2 (en)	2002-05-09
BR9809172A (pt)	2000-08-01
DE69842077D1 (de)	2011-02-10
EA002600B1 (ru)	2002-06-27
NO995819D0 (no)	1999-11-26
IL133008A0 (en)	2001-03-19
DE69828607T2 (de)	2006-01-05
HK1028042A1 (en)	2001-02-02
PL194980B1 (pl)	2007-07-31

Publication	Publication Date	Title
NO995817L (no)	1999-11-26	Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
NO20012583D0 (no)	2001-05-25	Quinoliner og quinoksalinforbindelser som PDGF-R- og/eller LCK-tyrosinkinase-inhibitorer
NO20012582L (no)	2001-07-19	Kinoline- og kinoksalinforbindelser som PDGF-reseptor- og/eller LCK-tyrosinkinaseinhibitorer
NO20012579L (no)	2001-07-19	Kinolin- og kinoksalinforbindelser
DK1000039T3 (da)	2004-08-16	Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
IS6326A (is)	2002-03-27	Týrósín kínasa latar
DE69839096D1 (de)	2008-03-20	Dispersion von cellulose
NO992336D0 (no)	1999-05-14	Raf-kinase-inhibitorer
BR9914167B1 (pt)	2011-03-09	compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
FI940414A7 (fi)	1994-07-29	Kinoliini- tai kinatsoliinijohdannaiset, niiden valmistus ja käyttö
DE60009888T2 (de)	2005-04-21	Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
FI955661A7 (fi)	1996-01-19	Substituoidut beta-aryyli- ja beta-heteroaryyli-alfa-syanoakryyliamidi johdannaiset tyrosiinikinaasi-inhibiittoreina
DE69734817D1 (de)	2006-01-12	Neuartige amp-aktivierte proteinkinase
DE69925866D1 (de)	2005-07-21	Aussermembranproteine, ihre gene, und deren verwendung
ZA984571B (en)	1999-01-21	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases
HUP0002219A3 (en)	2001-01-29	Quinoline and quinoxaline derivatives which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases and pharmaceutical compositions containing them
HK1038229A (en)	2002-03-08	Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
DK1226136T3 (da)	2005-04-25	Tyrosinkinaseinhibitor
FIU970056U0 (fi)	1997-01-31	Asuste
FI971352A0 (fi)	1997-04-02	Sytoplasminen tyrosiinikinaasi